[{
  "type": "article-journal",
  "title": "HYPOGLYCEMIC AND HYPOLIPEMIC EFFECTS OF β-GLUCAN DERIVED FROM AUREOBASIDIUM IN STZ-INDUCED DIABETIC RATS",
  "author": [
    {
      "family": "Choi",
      "given": ""
    },
    {
      "family": "Kim",
      "given": ""
    },
    {
      "family": "Jung",
      "given": ""
    },
    {
      "family": "Park",
      "given": ""
    },
    {
      "family": "Cho",
      "given": ""
    },
    {
      "family": "Ku",
      "given": ""
    },
    {
      "family": "Sohn",
      "given": ""
    }
  ],
  "issued": {
    "date-parts": [[2018]]
  },
  "container-title": "Journal of Animal and Plant Sciences",
  "ISSN": "1018-7081",
  "volume": "28",
  "issue": "2",
  "page": "660-668",
  "DOI": "NA",
  "abstract": "<p>The primary objective of the present study was to determine the effects of &#946;-glucan derived from <em>Aureobasidium</em> on diabetes and diabetic hyperlipemia in an animal model of streptozotocin (STZ)-induced diabetes. &#946;-glucan was orally administered to STZ-induced diabetic hyperlipemic Sprague-Dawley (SD) rats for 4 weeks beginning at 25 days after STZ administration (late diabetic hypoglycemic and hyperlipemia model). Changes in body weight were recorded throughout the study and blood glucose and serum low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglyceride, and total cholesterol (T-CHOL) levels were measured at 28 days after &#946;-glucan administration. The &#946;-glucan results were compared with those from rats that received Simvastatin (10 mg/kg). Following the occurrence of STZ-induced diabetes, the STZ control group exhibited decreases in body weight and serum HDL levels in conjunction with increases in blood glucose, serum LDL, triglyceride, and T-CHOL levels compared to the intact control group. However, serum LDL, triglyceride, and T-CHOL levels dramatically decreased in the STZ groups that received &#946;-glucan (62.5 and 125 mg/kg). The present results suggest that &#946;-glucan derived from <em>Aureobasidium</em> does not exert hypoglycemic effects in an SD rat model of STZ-induced diabetes. However, &#946;-glucan did have favorable effects in terms of attenuating complications related to diabetic hyperlipemia at a dose of 62.5 mg/kg/day or more. Therefore, &#946;-glucan may be a candidate as a novel hypolipemic agent designed specifically to treat diabetic complications related to hyperlipemia regardless of the severity of disease.</p>",
  "publisher": "Pakistan Agricultural Scientists Forum",
  "URL": "https://thejaps.org.pk/AbstractView.aspx?mid=2018-JAPS-240"
}]